Century Therapeutics (IPSC) Other Non-Current Liabilities (2024 - 2026)

Century Therapeutics (IPSC) has reported Other Non-Current Liabilities for 3 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 77.19% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 77.19% YoY), while the FY2025 annual figure was $3.8 million, down 57.0% from the prior year.
• Other Non-Current Liabilities declined to $1.9 million in Q1 2026 per IPSC's latest filing, from $3.8 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $9.3 million in Q2 2024 and bottomed at $20000.0 in Q1 2024.
• Historically, Other Non-Current Liabilities has averaged $6.6 million across 3 years, with a median of $8.7 million in 2024.
• Annual changes were most pronounced in 2025 — Other Non-Current Liabilities surged 42400.0% — and 2026, when it plunged 77.19%.
• Century Therapeutics' Other Non-Current Liabilities stood at $8.7 million in 2024, then slumped by 57.0% to $3.8 million in 2025, then slumped by 48.39% to $1.9 million in 2026.
• Business Quant data shows IPSC's Other Non-Current Liabilities at $1.9 million in Q1 2026, $3.8 million in Q4 2025, and $9.1 million in Q3 2025.